381 related articles for article (PubMed ID: 17334983)
1. Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma: children's Cancer Group (CCG) 7943.
Seibel NL; Krailo M; Chen Z; Healey J; Breitfeld PP; Drachtman R; Greffe B; Nachman J; Nadel H; Sato JK; Meyers PA; Reaman GH
Cancer; 2007 Apr; 109(8):1646-53. PubMed ID: 17334983
[TBL] [Abstract][Full Text] [Related]
2. Metastatic osteosarcoma.
Daw NC; Billups CA; Rodriguez-Galindo C; McCarville MB; Rao BN; Cain AM; Jenkins JJ; Neel MD; Meyer WH
Cancer; 2006 Jan; 106(2):403-12. PubMed ID: 16353204
[TBL] [Abstract][Full Text] [Related]
3. A phase I/II study of doxorubicin, ifosfamide, etoposide and interval methotrexate in patients with poor prognosis osteosarcoma.
McTiernan A; Meyer T; Michelagnoli MP; Lewis I; Whelan JS
Pediatr Blood Cancer; 2006 Mar; 46(3):345-50. PubMed ID: 16206197
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study.
Blaney SM; Needle MN; Gillespie A; Sato JK; Reaman GH; Berg SL; Adamson PC; Krailo MD; Bleyer WA; Poplack DG; Balis FM
Clin Cancer Res; 1998 Feb; 4(2):357-60. PubMed ID: 9516923
[TBL] [Abstract][Full Text] [Related]
5. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study.
Walterhouse DO; Lyden ER; Breitfeld PP; Qualman SJ; Wharam MD; Meyer WH
J Clin Oncol; 2004 Apr; 22(8):1398-403. PubMed ID: 15007087
[TBL] [Abstract][Full Text] [Related]
7. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
Meyers PA; Schwartz CL; Krailo MD; Healey JH; Bernstein ML; Betcher D; Ferguson WS; Gebhardt MC; Goorin AM; Harris M; Kleinerman E; Link MP; Nadel H; Nieder M; Siegal GP; Weiner MA; Wells RJ; Womer RB; Grier HE;
J Clin Oncol; 2008 Feb; 26(4):633-8. PubMed ID: 18235123
[TBL] [Abstract][Full Text] [Related]
8. Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457--a report from the Children's Oncology Group.
Bernstein ML; Devidas M; Lafreniere D; Souid AK; Meyers PA; Gebhardt M; Stine K; Nicholas R; Perlman EJ; Dubowy R; Wainer IW; Dickman PS; Link MP; Goorin A; Grier HE; ; ;
J Clin Oncol; 2006 Jan; 24(1):152-9. PubMed ID: 16382125
[TBL] [Abstract][Full Text] [Related]
9. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy.
Hawkins DS; Arndt CA
Cancer; 2003 Dec; 98(11):2447-56. PubMed ID: 14635080
[TBL] [Abstract][Full Text] [Related]
10. Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group study.
Kretschmar CS; Kletzel M; Murray K; Thorner P; Joshi V; Marcus R; Smith EI; London WB; Castleberry R
J Clin Oncol; 2004 Oct; 22(20):4119-26. PubMed ID: 15483021
[TBL] [Abstract][Full Text] [Related]
11. Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions.
Bacci G; Mercuri M; Briccoli A; Ferrari S; Bertoni F; Donati D; Monti C; Zanoni A; Forni C; Manfrini M
Cancer; 1997 Jan; 79(2):245-54. PubMed ID: 9010097
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of 3-day topotecan and cisplatin in elderly patients with small-cell lung cancer.
Fujiwara K; Ueoka H; Kiura K; Tabata M; Takigawa N; Hotta K; Umemura S; Sugimoto K; Shibayama T; Kamei H; Harita S; Okimoto N; Tanimoto M
Cancer Chemother Pharmacol; 2006 Jun; 57(6):755-60. PubMed ID: 16208519
[TBL] [Abstract][Full Text] [Related]
13. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial.
Leyvraz S; Pampallona S; Martinelli G; Ploner F; Perey L; Aversa S; Peters S; Brunsvig P; Montes A; Lange A; Yilmaz U; Rosti G;
J Natl Cancer Inst; 2008 Apr; 100(8):533-41. PubMed ID: 18398095
[TBL] [Abstract][Full Text] [Related]
14. Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome--the French pediatric experience.
Mialou V; Philip T; Kalifa C; Perol D; Gentet JC; Marec-Berard P; Pacquement H; Chastagner P; Defaschelles AS; Hartmann O
Cancer; 2005 Sep; 104(5):1100-9. PubMed ID: 16015627
[TBL] [Abstract][Full Text] [Related]
15. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience.
Van Winkle P; Angiolillo A; Krailo M; Cheung YK; Anderson B; Davenport V; Reaman G; Cairo MS
Pediatr Blood Cancer; 2005 Apr; 44(4):338-47. PubMed ID: 15503297
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis.
Patel SR; Papadopolous N; Raymond AK; Donato M; Seong CM; Yasko AW; Lewis VO; Lin PP; Champlin R; Benjamin RS
Cancer; 2004 Jul; 101(1):156-63. PubMed ID: 15222001
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
Rose PG; Smrekar M; Haba P; Fusco N; Rodriguez M
Am J Clin Oncol; 2008 Oct; 31(5):476-80. PubMed ID: 18838885
[TBL] [Abstract][Full Text] [Related]
18. Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study.
Hawkins DS; Bradfield S; Whitlock JA; Krailo M; Franklin J; Blaney SM; Adamson PC; Reaman G
Pediatr Blood Cancer; 2006 Nov; 47(6):790-4. PubMed ID: 16435380
[TBL] [Abstract][Full Text] [Related]
19. Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma.
Tas F; Derin D; Guney N; Camlica H; Aydiner A; Topuz E
Lung Cancer; 2007 Jul; 57(1):79-83. PubMed ID: 17383768
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group.
Frangoul H; Ames MM; Mosher RB; Reid JM; Krailo MD; Seibel NL; Shaw DW; Steinherz PG; Whitlock JA; Holcenberg JS
Clin Cancer Res; 1999 Dec; 5(12):3956-62. PubMed ID: 10632325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
